BVBrooke Vuong

Brooke Vuong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brooke Vuong has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Gillian Kuehner

    The Department of Surgery, Kaiser Permanente Vallejo Medical Center, Vallejo, CA (Kuehner)

    2 shared publications
  • Sharon B. Chang

    Department of Surgery, Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA

    2 shared publications
  • Alison C. Savitz

    Department of Surgery, Kaiser Permanente Walnut Creek Medical Center, Walnut Creek, CA

    1 shared publication
  • Alison Savitz

    The Department of Surgery, Kaiser Permanente Walnut Creek Medical Center, Walnut Creek, CA (Savitz)

    1 shared publication
  • Ana I. Jacinto

    Department of Surgery, University of California, Davis, Sacramento, CA

    1 shared publication
  • Cara Franken

    General Surgeon at the Modesto Medical Center in CA.

    1 shared publication

Latest Publications

  • Contemporary Review of the Management and Treatment of Young Breast Cancer Patients

    by Brooke Vuong, Ana I. Jacinto, Sharon B. Chang, Gillian E. Kuehner, Alison C. Savitz


  • Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women

    by Brooke Md Vuong, Jeanne Darbinian, Alison Savitz, Patience Odele, Lauren M. MD Perry, Lakhbir Sandhu, Laurel A Habel, Gillian Kuehner

    BACKGROUND: Young breast cancer (YBC) patients are a unique subpopulation that are often underrepresented in randomized clinical trials. Furthermore, large national cancer databases lack detailed information on recurrence, a meaningful oncologic outcome for young patients. STUDY DESIGN: A retrospective review of YBC patients (age 40 years or younger) with stage I to III breast cancer diagnosed from 2008 to 2018 was performed. Information on clinicopathologic characteristics, demographics, and outcomes was obtained from the electronic health record and chart review. Chi-square and Fisher’s exact tests were used for comparisons of categorical variables and parametric and nonparametric tests for continuous variables. RESULTS: The cohort included 1,431 women with a median follow-up of 4.8 years (range 0.3 to 12.9 years). The median age was 37 years (interquartile range 34 to 39). The study population included 598 (41.8%) White, 112 (7.8%) Black, 420 (29.4%) Asian/Pacific Islander, 281 (19.6%) Hispanic, and 20 (1.4%) “other” race/ethnicity patients. Tumor subtype was as follows: [1] hormone receptor (HR)+/human epidermal growth factor 2 (HER2–), grade (G) 1 to 2 = 541 (37.8%); [2] HR+/HER2–, G3 = 268 (18.7%); [3] HR+/HER2+ = 262 (18.3%); [4] HR–/HER2+ = 101 (7.1%); [5] HR–/HER2– = 259 (18.1%). The majority (64.2%) presented with stage II/III disease. There were 230 (16.1%) recurrences during follow-up; 74.8% were distant. Locoregional-only recurrence was seen in 17 of 463 (3.7%) patients who underwent breast conservation vs 41 of 968 (4.2%) patients undergoing mastectomy (p < 0.001). Recurrence varied by tumor subtype: [1] HR+/HER2–, G1 to 2 (14.0%); [2] HR+/HER2–, G3 (20.9%); [3] HR+/HER2+ (11.1%); [4] HR–/HER2+ (22.8%); [5] HR–/HER2– (17.8%) (p = 0.005). CONCLUSIONS: In this large, diverse YBC cohort, recurrences were most frequent among HR+/HER2–, G3, or HR–/HER2+ invasive tumors; most were distant. There were numerically similar locoregional-only recurrences after breast conservation vs mastectomy. Additional research is needed to identify predictors of recurrence.


  • Outpatient Mastectomy: Factors Influencing Patient Selection and Predictors of Return to Care

    by Brooke Vuong, Jennifer R. Dusendang, Sharon B. Chang, Margaret Ann Mentakis, Veronica C. Shim, Julie Schmittdiel, Gillian Kuehner

    BACKGROUND: After implementation of the Surgical Home Recovery (SHR) initiative for mastectomy within a large, integrated health delivery system, most patients are discharged on the day of the procedure. We sought to identify predictors of SHR and unplanned return to care (RTC). STUDY DESIGN: Mastectomy cases with and without reconstruction from October 2017 to August 2019 were analyzed. Patient characteristics, operative variables, and multimodal pain management were compared between admitted patients and SHR patients using logistic regression. We identified predictors of RTC in SHR patients, defined as 7-day readmission, reoperation, or emergency department visit. RESULTS: Of 2,648 mastectomies, 1,689 (64%) were outpatient procedures and the mean age of patients was 58.5 years. Predictors of SHR included perioperative IV acetaminophen (odds ratio [OR] 1.59; 95% CI, 1.28 to 1.97), perioperative opiates (OR 1.47; 95% CI, 1.06 to 2.02), and operation performed by a high-volume breast surgeon (OR 2.12; 95% CI, 1.42 to 3.18). Bilateral mastectomies (OR 0.70; 95% CI, 0.54 to 0.91), immediate reconstruction (OR 0.52; 95% CI, 0.39 to 0.70), and American Society of Anesthesiologists class 3 to 4 (OR 0.69; 95% CI, 0.54 to 0.87) decreased the odds of SHR. Of SHR patients, 111 of 1,689 patients (7%) experienced RTC. Patients with American Society of Anesthesiologists class 3 to 4 (OR 2.01; 95% CI, 1.29 to 3.14) and African American race (OR 2.30; 95% CI, 1.38 to 4.91) were more likely to RTC; receiving IV acetaminophen (OR 0.56; 95% CI, 0.35 to 0.88) and filling an opiate prescription (OR 0.51; 95% CI, 0.34 to 0.77) decreased the odds of RTC. CONCLUSIONS: Surgeon volume and multimodal pain medication increased the odds of SHR. Within the SHR group, American Society of Anesthesiologists Class 3 to 4 and African American patients increased the likelihood of RTC. This study helps optimize patient selection and perioperative practice for successful SHR.


  • Preferential Use of Total Thyroidectomy without Prophylactic Central Lymph Node Dissection for Early-Stage Papillary Thyroid Cancer: Oncologic Outcomes in an Integrated Health Plan

    by Meena Said, Michele Fujimoto, Cara Franken, Sunee Woo, Brooke Vuong, Philip I Haigh

    Meena Said, MD; Michele Fujimoto, MD; Cara Franken, MD; Sunee Woo, MD; Brooke Vuong, MD; Philip I Haigh, MD, MSc, FRCSC, FACS Perm J 2016 Fall;20(4